Exploring Allogeneic Stem Cell Transplant for Older Patients with Multiple Myeloma
Official title: Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Run by Center for International Blood and Marrow Transplant Research · NCT03127761 · Data updated 2026-11-12
This study is testing whether a stem cell transplant can help older patients with multiple myeloma, especially those with high-risk disease, to see how well it works compared to regular treatments.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 544 (estimated) |
| Sponsor | Center for International Blood and Marrow Transplant Research Research network |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Minneapolis, Minnesota) |
| Status | Recruiting |
| Started | July 25, 2017 |
| Main results expected | May 2027 |
| Study ends | April 2028 |
| Registry record updated | August 30, 2023 |
| Trial ID | NCT03127761 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are Medicare beneficiaries with stage II or III multiple myeloma or primary plasma cell leukemia who are eligible for alloHCT.
✕Probably not a fit
Patients with early-stage multiple myeloma or those not eligible for alloHCT may not receive benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study assesses the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in Medicare beneficiaries diagnosed with multiple myeloma, particularly focusing on those with high-risk disease. It aims to gather comprehensive clinical data on patients who are eligible for alloHCT and will receive the procedure at designated transplant centers in the U.S. The study will analyze pre- and post-transplant clinical status and outcomes to better understand the potential benefits and risks associated with this treatment option in older patients. By leveraging data from the Center for International Blood and Marrow Research, the study seeks to provide insights into the efficacy of alloHCT compared to standard therapies.
Why it matters
Potential benefit: If successful, this study could provide valuable information on the effectiveness of alloHCT as a potentially curative treatment for high-risk multiple myeloma patients.
How similar studies have gone: While alloHCT has been explored in various contexts, this specific focus on older Medicare beneficiaries with high-risk multiple myeloma is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Medicare beneficiary * Stage II or III multiple myeloma and/or primary plasma cell leukemia * Eligible to receive an allogeneic HCT from any suitable allogeneic donor (as determined by the transplant center) including umbilical cord blood * Will receive allogeneic HCT at a US transplant center * Agree to submit comprehensive clinical data on their pre- and post-transplant clinical status and outcomes to the CIBMTR
Where it's running
-
Center for International Blood and Marrow Transplant Research
Minneapolis, Minnesota, United States Recruiting
Study contacts
- Study coordinator: Mona Patel
- Email: mopatel@mcw.edu
- Phone: 414-805-0655
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
-
Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma
This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.
-
SMS text check-ins to track symptoms for people with plasma cell disorders
This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.
-
Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma
This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.